Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Atypical or second generation antipsychotic used in the treatment of schizophrenia and the depressive phase of bipolar disorder. Oral administration once daily.
It is excreted in breast milk in a clinically insignificant amount and no problems were observed in one infant whose mother was taking it. Plasma levels in that infant were very low. (Keightley 2020)
Its pharmacokinetic data (very high percentage of protein binding, very large volume of distribution and moderately high molecular weight) explain the negligible passage into breast milk observed.
Lurasidone has little or no significant effect on prolactin levels. (Peuskens 2014)
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.
See below the information of this related product: